Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Phase 1 Completed 16 enrolled Vertex Pharmaceuticals Incorporated

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with moderate hepatic impairment and in matched healthy participants.

Timeline

Start: 2022-07-22
Primary completion: 2023-03-16
Completion: 2023-03-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vanzacaftor	Small molecule	—	Oral

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Summary

Timeline

Drugs

Indications